$4.53 Billion in Sales Expected for Stryker Co. (NYSE:SYK) This Quarter

Equities analysts expect Stryker Co. (NYSE:SYKGet Rating) to report sales of $4.53 billion for the current quarter, Zacks reports. Ten analysts have made estimates for Stryker’s earnings, with the highest sales estimate coming in at $4.58 billion and the lowest estimate coming in at $4.45 billion. Stryker posted sales of $4.29 billion in the same quarter last year, which suggests a positive year over year growth rate of 5.6%. The company is expected to issue its next earnings report on Monday, January 1st.

On average, analysts expect that Stryker will report full-year sales of $18.42 billion for the current year, with estimates ranging from $18.28 billion to $18.56 billion. For the next financial year, analysts anticipate that the business will post sales of $19.74 billion, with estimates ranging from $19.42 billion to $19.96 billion. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Stryker.

Stryker (NYSE:SYKGet Rating) last posted its quarterly earnings results on Thursday, April 28th. The medical technology company reported $1.97 earnings per share for the quarter, topping analysts’ consensus estimates of $1.95 by $0.02. Stryker had a net margin of 11.56% and a return on equity of 24.09%. The business had revenue of $4.30 billion for the quarter, compared to the consensus estimate of $4.19 billion. During the same period in the prior year, the business posted $1.93 earnings per share. Stryker’s revenue for the quarter was up 8.8% compared to the same quarter last year.

Several equities analysts have commented on the stock. BTIG Research increased their target price on shares of Stryker from $273.00 to $278.00 in a research report on Monday, April 18th. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research report on Monday. TheStreet downgraded shares of Stryker from a “b” rating to a “c+” rating in a research report on Monday. SVB Leerink lowered their target price on shares of Stryker from $300.00 to $285.00 and set an “outperform” rating on the stock in a research report on Friday, January 28th. Finally, Morgan Stanley lowered their target price on shares of Stryker from $305.00 to $275.00 and set an “equal weight” rating on the stock in a research report on Monday, January 31st. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Stryker has an average rating of “Buy” and an average target price of $291.44.

A number of institutional investors and hedge funds have recently made changes to their positions in SYK. Wellington Management Group LLP lifted its stake in Stryker by 43.8% during the third quarter. Wellington Management Group LLP now owns 12,408,440 shares of the medical technology company’s stock worth $3,272,353,000 after purchasing an additional 3,780,982 shares during the period. Norges Bank bought a new position in shares of Stryker in the fourth quarter valued at approximately $816,519,000. AustralianSuper Pty Ltd bought a new position in shares of Stryker in the first quarter valued at approximately $295,397,000. BlackRock Inc. raised its stake in shares of Stryker by 4.5% in the third quarter. BlackRock Inc. now owns 24,204,161 shares of the medical technology company’s stock valued at $6,383,121,000 after acquiring an additional 1,035,957 shares during the last quarter. Finally, First Trust Advisors LP raised its stake in shares of Stryker by 6,917.1% in the fourth quarter. First Trust Advisors LP now owns 703,744 shares of the medical technology company’s stock valued at $188,195,000 after acquiring an additional 693,715 shares during the last quarter. Hedge funds and other institutional investors own 74.52% of the company’s stock.

NYSE SYK opened at $241.36 on Friday. Stryker has a 1-year low of $230.16 and a 1-year high of $281.16. The company has a current ratio of 1.98, a quick ratio of 1.18 and a debt-to-equity ratio of 0.92. The company has a market capitalization of $91.27 billion, a PE ratio of 45.89, a price-to-earnings-growth ratio of 2.69 and a beta of 0.99. The firm’s fifty day simple moving average is $259.74 and its 200-day simple moving average is $260.08.

The business also recently announced a quarterly dividend, which will be paid on Friday, July 29th. Investors of record on Thursday, June 30th will be paid a $0.695 dividend. This represents a $2.78 annualized dividend and a dividend yield of 1.15%. The ex-dividend date is Wednesday, June 29th. Stryker’s payout ratio is presently 52.85%.

About Stryker (Get Rating)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.

Further Reading

Get a free copy of the Zacks research report on Stryker (SYK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.